We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Breast Cancer Diagnostic Blood Test Set for Imminent Availability

By LabMedica International staff writers
Posted on 15 Dec 2015
Print article
Image: Videssa Breast uses a combination of multiple serum protein biomarkers, multiple tumor associated autoantibodies, patient clinical data, and a highly sensitive ELISA-based platform to deliver an accurate diagnosis (Photo courtesy of Provista Diagnostics, Inc.).
Image: Videssa Breast uses a combination of multiple serum protein biomarkers, multiple tumor associated autoantibodies, patient clinical data, and a highly sensitive ELISA-based platform to deliver an accurate diagnosis (Photo courtesy of Provista Diagnostics, Inc.).
A blood test for breast cancer diagnosis in women with questionable mammographic findings and/or dense breast tissue is due for marketing release in early 2016.

Clinical data supporting the effectiveness of the Provista Diagnostics, Inc. (New York, NY, USA) Vanessa Breast assay was presented by Dr. Ana Lournco, a radiologist at Rhode Island Medical Imaging (RI, USA), in a presentation on December 3, 2015, at the 101st Scientific Assembly & Annual Meeting of the Radiological Society of North America in Chicago (RSNA; IL, USA).

Videssa Breast is intended for use in women between the ages of 25–75 years, who have questionable mammographic finding and/or dense breast tissue. In combination with clinical and radiological evaluations, Videssa Breast was designed to accurately detect the presence or absence of invasive breast cancer/ductal carcinoma in situ (DCIS) and reduce unnecessary follow-up procedures such as further imaging and biopsies. Videssa Breast is a protein-based blood test that can accurately detect the presence or absence of breast cancer. Videssa Breast detects breast cancer, rather than assessing a patient's risk for developing cancer in the future by identifying biomarkers that are early warning signals of breast cancer.

Provista's prospective, blinded, randomized, study enrolled over 500 patients from 10 breast cancer centers across the United States and included women ages 25–75 who had a BI-RADS 3 (probably benign) or BI-RADS 4 (suspicious) finding on imaging. Data from the study demonstrated the ability of Provista's biomarker assay to accurately detect the presence or absence of invasive breast cancer and/or DCIS with high sensitivity, specificity, negative predicative value (NPV), and positive predictive value (PPV).

"Provista's technology is not only groundbreaking as a complimentary diagnostic, but is also backed by strong, prospective clinical trial data," said Dr. Lourenco. "I chose to present their findings because I wanted to ensure my fellow radiologists learned of it."

"Provista is honored to have Dr. Lourenco present our data at this year's Radiological Society of North America meeting," said Dr. David Reese, president and CEO of Provista Diagnostics. "As a participant of our clinical trials and a well-respected radiologist, Dr. Lourenco provides valuable insight and validity to our data amongst a large group of peers."

Related Links:

Provista Diagnostics, Inc.
Rhode Island Medical Imaging


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.